KemPharm (NASDAQ:KMPH) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
Earnings and Valuation
This table compares KemPharm and Agios Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Agios Pharmaceuticals||$43.01 million||93.05||-$314.67 million||($6.75)||-10.22|
KemPharm has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than KemPharm, indicating that it is currently the more affordable of the two stocks.
This table compares KemPharm and Agios Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
39.2% of KemPharm shares are held by institutional investors. Comparatively, 93.6% of Agios Pharmaceuticals shares are held by institutional investors. 25.9% of KemPharm shares are held by insiders. Comparatively, 3.0% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
KemPharm has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for KemPharm and Agios Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KemPharm presently has a consensus price target of $11.60, suggesting a potential upside of 336.09%. Agios Pharmaceuticals has a consensus price target of $97.50, suggesting a potential upside of 41.28%. Given KemPharm’s stronger consensus rating and higher possible upside, equities research analysts clearly believe KemPharm is more favorable than Agios Pharmaceuticals.
KemPharm beats Agios Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder. It also provides APADAZ, an immediate-release (IR) combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. In addition, the company develops KP201/IR, an acetaminophen-free immediate-release formulation of APADAZ for treating short-term management of acute pain; and KP511/ER and KP511/IR hydromorphone product candidates for the treatment of pain. Further, it is developing KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. The company was founded in 2006 and is headquartered in Coralville, Iowa.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.